OncoMatch/Kidney Cancer (RCC)/MET
Kidney Cancer (RCC)MET Clinical Trials
1 recruiting trials·Updated daily from ClinicalTrials.gov
MET alterations — including mutation, amplification, and fusion — are the defining drivers of papillary type 1 RCC and occur as secondary events in other subtypes. Savolitinib (a selective MET inhibitor) demonstrated activity in MET-driven papillary RCC (SAVOIR/CALYPSO). Trials investigate MET inhibitor monotherapy and combinations for MET-driven non-clear cell RCC and MET-amplified acquired resistance to prior therapies.
Top recruiting
Top recruiting MET Kidney Cancer (RCC) trials
Ranked by phase and US site count. See all 1 trials matched to your profile →
Other Kidney Cancer (RCC) biomarkers
Browse other molecular targets with active Kidney Cancer (RCC) trials.